Lancet Oncol: Efficacy of dabrafenib combined with trametinib in BRAFV600E mutation-positive glioma

Glioma is the most common primary brain tumor
.

The 2016 WHO standard classifies gliomas into different subtypes and grades based on histological, molecular and genetic characteristics (especially IDH mutation status and 1p/19q deletion)

This study is an open-label, single-arm Phase 2 study conducted in 27 locations in 13 countries to evaluate the use of dabrafenib in combination with trametinib for high-grade BRAF ^V600E mutations that are positive for recurrent or progressive BRAF ^V600E mutations.
And the activity and safety of low-grade gliomas
.

^V600E

The study recruited 18-year-old patients with high-grade or low-grade glioma with EOCG performance status of 0-2 and BRAF ^V600E mutations and were given darafenib (150 mg, 2/day) + trameti Nitraria (2 mg, 1/day) is treated until intolerable toxicity, disease progression, or death occurs
.

What is in the hospital is the objective response rate assessed by the investigator

^V600E

Progression-free survival and overall survival of patients with high-grade glioma

Progression-free survival and overall survival of patients with high-grade glioma

From April 17, 2014 to July 25, 2018, the high-grade glioma cohort recruited 45 patients (of which 31 were glioblastomas), and the low-grade glioma cohort recruited 13 patients
.

As of September 14, 2020, the high-grade glioma cohort had been followed up for a median of 12.

The high-grade glioma cohort was followed up for a median of 12.

Progression-free survival and overall survival of patients with low-grade glioma

Progression-free survival and overall survival of patients with low-grade glioma

Thirty-one (53%) patients reported side effects of grade 3 and above, the most common being fatigue (5 cases [9%]), decreased neutrophil count (5 cases [9%]), headache (3 cases) [5%]) and neutropenia (3 cases [5%])
.

In conclusion, dabrafenib combined with trametinib has shown clinically significant therapeutic activity in relapsed or refractory high-grade gliomas and low-grade gliomas carrying BRAF ^V600E mutations, and the safety can be
.

Darafenib combined with trametinib has shown clinically significant therapeutic activity in relapsed or refractory high-grade gliomas and low-grade gliomas carrying BRAF ^V600E mutations, and the safety is good
.

Darafenib combined with trametinib has shown clinically significant therapeutic activity in relapsed or refractory high-grade gliomas and low-grade gliomas carrying BRAF ^V600E mutations, and the safety is good

Original source:

Patrick Y Wen, et al.

Dabrafenib plus trametinib in patients with BRAFV600E- mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial in this message